The Mag

Antibiotic crisis: five minutes to midnight

In this issue:

  • Antibiotic crisis: five minutes to midnight
  • Digital Health: A bright future
  • Bioeconomy: Industry rediscovers wood
  • Interview with Mark Fahy, about why we’re seeing IPOs again
  • Cancer: Oncologists evaluate clinical benefits in novel therapies
  • CROs & CMOs: Generalists and specialists in the growing outsourcing market
  • News from our partner associations European Biotechnology Network, EAPB, EDMA, DIA, BIO Deutschland and the Swiss Biotech Association